In 2024, the FDA granted tumour agnostic accelerated approval to trastuzumab deruxtecan for the treatment of patients with pretreated advanced HER2-positive (immunohistochemistry [IHC] 3+) solid tumours without alternative therapeutic options. The gene discussed is ERBB2; the disease is neoplasm.